HumanaH - Hu3s193 in the Treatment of Advanced Breast Cancer After Hormonal Therapy

Phase 2 Terminated 23 enrolled Cancer Institute of the State of São Paulo Fundação Faculdade de Medicina · collab Recepta Biopharma · collab

NaSingle-groupOpen-labelTreatment

Summary

The humanized monoclonal antibody against Lewis Y antigen (Hu3S193) has been demonstrated to be safe in previous studies and has also been indicated as potential intervention in breast cancer. The study of this new agent in advanced breast cancer may contribute to the development of new strategies for patients that progressed after hormonal treatment.

Timeline

Start: 2013-11
Primary completion: 2015-10
Completion: 2018-05-25

Outcome

Outcome not reported

Stopped: “futility”

Publications

Testa L, Mano M, Arai RJ, Bonadio RC, Serrano SV, Zorzetto MMC, Crocamo S, Smaletz O, Freitas-Junior R, Hoff PM. Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy. Clinics (Sao Paulo). 2021 Oct 11;76:e3146. doi: 10.6061/clinics/2021/e3146. eCollection 2021.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	hu3S193	Monoclonal antibody	20 mg/m2	Intravenous